Flow cytometry in cancer stem cell analysis and separation

Cytometry Part A

Volumn 81 A, Issue 4, 2012, Pages 284-293

  Greve, Burkhard ^a   Kelsch, Reinhard ^a   Spaniol, Kristina ^b   Eich, Hans Theodor ^a   Götte, Martin ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Cancer stem cells; FACS; Flow cytometry; Molecular beacon; Stem cell markers

Indexed keywords

ABC TRANSPORTER; ALDEHYDE DEHYDROGENASE; MEMBRANE ANTIGEN;

ANIMAL; CANCER STEM CELL; CYTOLOGY; FLOW CYTOMETRY; HUMAN; METABOLISM; METHODOLOGY; REVIEW;

ALDEHYDE DEHYDROGENASE; ANIMALS; ANTIGENS, SURFACE; ATP-BINDING CASSETTE TRANSPORTERS; FLOW CYTOMETRY; HUMANS; NEOPLASTIC STEM CELLS;

EID: 84858792036     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.22022     Document Type: Review

References (163)

1. Venere M, Fine HA, Dirks PB, Rich JN. Cancer stem cells in gliomas: Identifying and understanding the apex cell in cancer's hierarchy. Glia 2011; 59: 1148-1154.
2. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
3. Bomken S, Fiser K, Heidenreich O, Vormoor J. Understanding the cancer stem cell. Br J Cancer 2010; 103: 439-445.
4. Fabian A, Barok M, Vereb G, Szollosi J. Die hard: Are cancer stem cells the Bruce Willises of tumor biology? Cytometry A 2009; 75A: 67-74.
5. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells-Perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66: 9339-9344.
6. Soltanian S, Matin MM. Cancer stem cells and cancer therapy. Tumor Biol 2011; 32: 425-440.
7. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007; 23: 675-699.
8. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, Mackay A, Grigoriadis A, Tutt A, Ashworth A, et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010; 7: 403-417.
9. Vermeulen L, Todaro M, de Sousa Mello F, Sprick MR, Kemper K, Perez Alea M, Richel DJ, Stassi G, Medema JP. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci USA 2008; 105: 13427-13432.
10. Ratajczak MZ. Cancer stem cells-Normal stem cells Jedi that went over to the dark side. Folia Histochem Cytobiol 2005; 43: 175-181.
11. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer stem cells. Br J Cancer 2010; 102: 789-795.
12. LaBarge MA. The difficulty of targeting cancer stem cell niches. Clin Cancer Res 2010; 16: 3121-3129.
13. Hosonuma S, Kobayashi Y, Kojo S, Wada H, Seino K, Kiguchi K, Ishizuka B. Clinical significance of side population in ovarian cancer cells. Hum Cell 2011; 24: 9-12.
14. Tsai LL, Yu CC, Chang YC, Yu CH, Chou MY. Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. J Oral Pathol Med 2011; 40: 621-628.
15. Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, Chang HT, Chen YS, Lin TW, Hsu HS, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 2010; 70: 10433-10444.
16. Leiros GJ, Balana ME. Metastatic cancer stem cells: New molecular targets for cancer therapy. Curr Pharm Biotechnol 2011; 12: 1909-1922.
17. Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, Allan AL. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 2009; 13: 2236-2252.
18. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
19. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003; 100: 15178-15183.
20. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951.
21. Collins AT, Maitland NJ. Prostate cancer stem cells. Eur J Cancer 2006; 42: 1213-1218.
22. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007; 67: 4827-4833.
23. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005; 65: 3025-3029.
24. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007; 132: 2542-2556.
25. Lee HE, Kim JH, Kim YJ, Choi SY, Kim SW, Kang E, Chung IY, Kim IA, Kim EJ, Choi Y, et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer 2011; 104: 1730-1738.
26. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008; 8: 545-554.
27. Moserle L, Ghisi M, Amadori A, Indraccolo S. Side population and cancer stem cells: Therapeutic implications. Cancer Lett 2010; 288: 1-9.
28. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009; 458: 780-893.
29. Maitland NJ, Collins AT. Prostate cancer stem cells: A new target for therapy. J Clin Oncol 2008; 26: 2862-2870.
30. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK. A distinct side population of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004; 101: 14228-14233.
31. Baumann M, Krause M. CD44: A cancer stem cell-related biomarker with predictive potential for radiotherapy. Clin Cancer Res 2010; 16: 5091-5093.
32. Hongo K, Tanaka J, Tsuno NH, Kawai K, Nishikawa T, Shuno Y, Sasaki K, Kaneko M, Hiyoshi M, Sunami E, et al. CD133(-) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(+) cells, dependent on the beta 1-integrin signaling. J Surg Res 2011; Epub ahead of print.
33. Tarnok A, Ulrich H, Bocsi J. Phenotypes of stem cells from diverse origin. Cytometry A 2010; 77A: 6-10.
34. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65: 9328-9337.
35. Tabor MH, Clay MR, Owen JH, Bradford CR, Carey TE, Wolf GT, Prince ME. Head and neck cancer stem cells: The side population. Laryngoscope 2011; 121: 527-533.
36. Hadnagy A, Gaboury L, Beaulieu R, Balicki D. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 2006; 312: 3701-3710.
37. Douville J, Beaulieu R, Balicki D. ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev 2009; 18: 17-25.
38. Zimmerlin L, Donnenberg VS, Donnenberg AD. Rare event detection and analysis in flow cytometry: Bone marrow mesenchymal stem cells, breast cancer stem/progenitor cells in malignant effusions, and pericytes in disaggregated adipose tissue. Methods Mol Biol 2011; 699: 251-273.
39. Kentrou NA, Tsagarakis NJ, Tzanetou K, Damala M, Papadimitriou KA, Skoumi D, Stratigaki A, Anagnostopoulos NI, Malamou-Lada E, Athanassiadou P, et al. An improved flow cytometric assay for detection and discrimination between malignant cells and atypical mesothelial cells, in serous cavity effusions. Cytometry B Clin Cytom 2011; 80B: 324-334.
40. Greve B, Beller C, Cassens U, Sibrowski W, Gohde W. The impact of erythrocyte lysing procedures on the recovery of hematopoietic progenitor cells in flow cytometric analysis. Stem Cells 2006; 24: 793-799.
41. Cassens U, Greve B, Tapernon K, Nave B, Severin E, Sibrowski W, Gohde W. A novel true volumetric method for the determination of residual leucocytes in blood components. Vox Sang 2002; 82: 198-206.
42. Panchision DM, Chen HL, Pistollato F, Papini D, Ni HT, Hawley TS. Optimized flow cytometric analysis of central nervous system tissue reveals novel functional relationships among cells expressing CD133, CD15, and CD24. Stem Cells 2007; 25: 1560-1570.
43. Harichandan A, Buhring HJ. Prospective isolation of human MSC. Best Pract Res Clin Haematol 2011; 24: 25-36.
44. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007; 25: 2739-2749.
45. Woodward WA, Sulman EP. Cancer stem cells: Markers or biomarkers? Cancer Metastasis Rev 2008; 27: 459-470.
46. Yang YM, Chang JW. Current status and issues in cancer stem cell study. Cancer Invest 2008; 26: 741-755.
47. Klonisch T, Wiechec E, Hombach-Klonisch S, Ande SR, Wesselborg S, Schulze-Osthoff K, Los M. Cancer stem cell markers in common cancers-Therapeutic implications. Trends Mol Med 2008; 14: 450-460.
48. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
49. Okamoto OK, Oba-Shinjo SM, Lopes L, Nagahashi Marie SK. Expression of HOXC9 and E2F2 are upregulated in CD133(+) cells isolated from human astrocytomas and associate with transformation of human astrocytes. Biochim Biophys Acta 2007; 1769: 437-442.
50. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
51. Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F, Paredes J. Breast cancer stem cell markers CD44, CD24 and ALDH1: Expression distribution within intrinsic molecular subtype. J Clin Pathol 2011; 64: 937-946.
52. Maitland NJ, Bryce SD, Stower MJ, Collins AT. Prostate cancer stem cells: A target for new therapies. Ernst Schering Found Symp Proc 2006;5: 155-179.
53. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
54. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
55. Buccisano F, Rossi FM, Venditti A, Del Poeta G, Cox MC, Abbruzzese E, Rupolo M, Berretta M, Degan M, Russo S, et al. CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias. Br J Haematol 2004; 125: 203-212.
56. Castor A, Nilsson L, Astrand-Grundstrom I, Buitenhuis M, Ramirez C, Anderson K, Strombeck B, Garwicz S, Bekassy AN, Schmiegelow K, et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 2005; 11: 630-637.
57. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, Ghivizzani SC, Ignatova TN, Steindler DA. Stem-like cells in bone sarcomas: Implications for tumorigenesis. Neoplasia 2005; 7: 967-976.
58. Marzesco AM, Janich P, Wilsch-Brauninger M, Dubreuil V, Langenfeld K, Corbeil D, Huttner WB. Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. J Cell Sci 2005; 118: 2849-2858.
59. Donnenberg VS, Donnenberg AD, Zimmerlin L, Landreneau RJ, Bhargava R, Wetzel RA, Basse P, Brufsky AM. Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. Cytometry B Clin Cytom 2010; 78B: 287-301.
60. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-115.
61. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104: 10158-10163.
62. Haraguchi N, Ohkuma M, Sakashita H, Matsuzaki S, Tanaka F, Mimori K, Kamohara Y, Inoue H, Mori M. CD133+CD44+ population efficiently enriches colon cancer initiating cells. Ann Surg Oncol 2008; 15: 2927-2933.
63. Chen KL, Pan F, Jiang H, Chen JF, Pei L, Xie FW, Liang HJ. Highly enriched CD133(+)CD44 (+) stem-like cells with CD133 (+)CD44 (high) metastatic subset in HCT116 colon cancer cells. Clin Exp Metastasis 2011; 28: 751-763.
64. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Investig 2008; 118: 2111-2120.
65. Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol 2010; 8: 147.
66. Götte M, Greve B, Kelsch R, Müller-Uthoff H, Weiss K, Kharabi Masouleh B, Sibrowski W, Kiesel L, Buchweitz O. The adult stem cell marker musashi-1 modulates endometrial carcinoma cell cycle progression and apoptosis via notch-1 and p21(WAF1/CIP1). Int J Cancer 2010; 129: 2042-2049.
67. Shi C, Tian R, Wang M, Wang X, Jiang J, Zhang Z, Li X, He Z, Gong W, Qin R. CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther 2010; 10: 1182-1190.
68. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y, Wang TC. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009; 27: 1006-1020.
69. Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J, Li J. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer 2010; 126: 2067-2078.
70. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT, Fan ST. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008; 13: 153-166.
71. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136: 1012-1024.
72. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007; 120: 1444-1450.
73. Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, Banerjee M, Mao Y, Kotarski J, Wicha MS, et al. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer 2011; 130: 29-39.
74. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68: 4311-4320.
75. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
76. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008; 98: 756-765.
77. Brown MD, Gilmore PE, Hart CA, Samuel JD, Ramani VA, George NJ, Clarke NW. Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations. Prostate 2007; 67: 1384-1396.
78. Bussolati B, Bruno S, Grange C, Ferrando U, Camussi G. Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J (Official Publication of the Federation of American Societies for Experimental Biology) 2008; 22: 3696-3705.
79. Prince ME, Ailles LE. Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol (Official Journal of the American Society of Clinical Oncology) 2008; 26: 2871-2875.
80. Lin WM, Karsten U, Goletz S, Cheng RC, Cao Y. Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells. Int J Exp Pathol 2011; 92: 97-105.
81. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI, Armstrong SA. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010; 327: 1650-1653.
82. Hu ZZ, Kagan BL, Ariazi EA, Rosenthal DS, Zhang L, Li JV, Huang H, Wu C, Jordan VC, Riegel AT, et al. Proteomic analysis of pathways involved in estrogen-induced growth and apoptosis of breast cancer cells. PloS one 2011; 6: e20410.
83. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, Suri P, Wicha MS. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006; 66: 6063-6071.
84. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
85. Hoek KS, Goding CR. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res 2010; 23: 746-759.
86. Watanabe M, Ogawa Y, Itoh K, Koiwa T, Kadin ME, Watanabe T, Okayasu I, Higashihara M, Horie R. Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma. Lab Invest 2008; 88: 48-57.
87. Stindl R. Defining the steps that lead to cancer: Replicative telomere erosion, aneuploidy and an epigenetic maturation arrest of tissue stem cells. Med Hypotheses 2008; 71: 126-140.
88. Lambert JF, Liu M, Colvin GA, Dooner M, McAuliffe CI, Becker PS, Forget BG, Weissman SM, Quesenberry PJ. Marrow stem cells shift gene expression and engraftment phenotype with cell cycle transit. J Exp Med 2003; 197: 1563-1572.
89. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009; 28: 209-218.
90. Pallini R, Casalbore P, Mercanti D, Maggiano N, Larocca LM. Phenotypic change of human cultured meningioma cells. J Neurooncol 2000; 49: 9-17.
91. Dützmann S, Reiss S, Seifert V, Kögel D, Pennartz S. Standardized tissue dissociation and removal of myelin debris optimize isolation of cells from human brain tumors. Available at: 2010.
92. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ. Purification and unique properties of mammary epithelial stem cells. Nature 2006; 439: 993-997.
93. Xiao J, Addabbo RM, Lauer JL, Fields GB, Baum J. Local conformation and dynamics of isoleucine in the collagenase cleavage site provide a recognition signal for matrix metalloproteinases. J Biol Chem 2010; 285: 34181-34190.
94. Keysar SB, Jimeno A. More than markers: Biological significance of cancer stem cell-defining molecules. Mol Cancer Therap 2010; 9: 2450-2457.
95. Ding XW, Wu JH, Jiang CP. ABCG2: A potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 2010; 86: 631-637.
96. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7: 1028-1034.
97. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005; 65: 6207-6219.
98. Eyler CE, Rich JN. Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 26: 2839-2845.
99. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284.
100. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: The cancer stem cell hypothesis. J Clin Pharmacol 2005; 45: 872-877.
101. Li WQ, Li YM, Tao BB, Lu YC, Hu GH, Liu HM, He J, Xu Y, Yu HY. Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance. Med Sci Monit 2010; 16: HY27-HY30.
102. Paduch R, Jakubowicz-Gil J, Niedziela P. Hepatocyte growth factor (HGF), heat shock proteins (HSPs) and multidrug resistance protein (MRP) expression in coculture of colon tumor spheroids with normal cells after incubation with interleukin-1beta (IL-1beta) and/or camptothecin (CPT-11). Indian J Exp Biol 2010; 48: 354-364.
103. Chuthapisith S, Eremin J, El-Sheemey M, Eremin O. Breast cancer chemoresistance: Emerging importance of cancer stem cells. Surg Oncol 2010; 19: 27-32.
104. Misawa A, Katayama R, Koike S, Tomida A, Watanabe T, Fujita N. AP-1-dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells. Oncol Res 2010; 19: 23-33.
105. Tang QL, Liang Y, Xie XB, Yin JQ, Zou CY, Zhao ZQ, Shen JN, Wang J. Enrichment of osteosarcoma stem cells by chemotherapy. Chin J Cancer 2011; 30: 426-432.
106. Dou J, Jiang C, Wang J, Zhang X, Zhao F, Hu W, He X, Li X, Zou D, Gu N. Using ABCG2-molecule-expressing side population cells to identify cancer stem-like cells in a human ovarian cell line. Cell Biol Int 2011; 35: 227-234.
107. Hiraga T, Ito S, Nakamura H. Side population in MDA-MB-231 human breast cancer cells exhibits cancer stem cell-like properties without higher bone-metastatic potential. Oncol Rep 2011; 25: 289-296.
108. Hu W, Liu W. Side populations of glioblastoma cells are less sensitive to HSV-TK/GCV suicide gene therapy system than the nonside population. In Vitro Cell Dev Biol Anim 2010; 46: 497-501.
109. Gross E, L'Faqihi-Olive FE, Ysebaert L, Brassac M, Struski S, Kheirallah S, Fournie JJ, Laurent G, Quillet-Mary A. B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cells. Leukemia 2010; 24: 1885-1892.
110. Chikazawa N, Tanaka H, Tasaka T, Nakamura M, Tanaka M, Onishi H, Katano M. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res 2010; 30: 2041-2048.
111. Srivastava VK, Nalbantoglu J. Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem-like phenotype. Cytometry A 2008; 73A: 940-948.
112. Wu C, Alman BA. Side population cells in human cancers. Cancer Lett 2008; 268: 1-9.
113. Goodell MA. Stem cell identification and sorting using the Hoechst 33342 side population (SP). Curr Protoc Cytom 2005;9: 18.
114. Udomsakdi C, Eaves CJ, Sutherland HJ, Lansdorp PM. Separation of functionally distinct subpopulations of primitive human hematopoietic cells using rhodamine-123. Exp Hematol 1991; 19: 338-342.
115. Liu WH, Qian NS, Li R, Dou KF. Replacing Hoechst33342 with rhodamine123 in isolation of cancer stem-like cells from the MHCC97 cell line. Toxicol In Vitro 2010; 24: 538-545.
116. Bertoncello I, Williams B. Hematopoietic stem cell characterization by Hoechst 33342 and rhodamine 123 staining. Methods Mol Biol 2004; 263: 181-200.
117. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95: 15665-15670.
118. Garcia-Escarp M, Martinez-Munoz V, Sales-Pardo I, Barquinero J, Domingo JC, Marin P, Petriz J. Flow cytometry-based approach to ABCG2 function suggests that the transporter differentially handles the influx and efflux of drugs. Cytometry A 2004; 62A: 129-138.
119. Telford WG. Stem cell side population analysis and sorting using DyeCycle violet. Curr Protoc Cytom 2010;9: 30.
120. Telford WG, Bradford J, Godfrey W, Robey RW, Bates SE. Side population analysis using a violet-excited cell-permeable DNA binding dye. Stem Cells 2007; 25: 1029-1036.
121. Gao Q, Geng L, Kvalheim G, Gaudernack G, Suo Z. Identification of cancer stem-like side population cells in ovarian cancer cell line OVCAR-3. Ultrastruct Pathol 2009; 33: 175-181.
122. Geng S, Wang Q, Wang J, Hu Z, Liu C, Qiu J, Zeng W. Isolation and identification of a distinct side population cancer cells in the human epidermal squamous cancer cell line A431. Arch Dermatol Res 2011; 303: 181-189.
123. Mo SL, Li J, Loh YS, Brown RD, Smith AL, Chen Y, Joshua D, Roufogalis BD, Li GQ, Fan K, et al. Factors influencing the abundance of the side population in a human myeloma cell line. Bone Marrow Res 2011; 2011: 524845.
124. Montanaro F, Liadaki K, Schienda J, Flint A, Gussoni E, Kunkel LM. Demystifying SP cell purification: Viability, yield, and phenotype are defined by isolation parameters. Exp Cell Res 2004; 298: 144-154.
125. Ibrahim SF, Diercks AH, Petersen TW, van den Engh G. Kinetic analyses as a critical parameter in defining the side population (SP) phenotype. Exp Cell Res 2007; 313: 1921-1926.
126. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009; 4: 226-235.
127. Yao J, Cai HH, Wei JS, An Y, Ji ZL, Lu ZP, Wu JL, Chen P, Jiang KR, Dai CC, et al. Side population in the pancreatic cancer cell lines SW1990 and CFPAC-1 is enriched with cancer stem-like cells. Oncol Rep 2010; 23: 1375-1382.
128. Kawanabe N, Murakami K, Takano-Yamamoto T. The presence of ABCG2-dependent side population cells in human periodontal ligaments. Biochem Biophys Res Commun 2006; 344: 1278-1283.
129. Sladek NE. Human aldehyde dehydrogenases: Potential pathological, pharmacological, and toxicological impact. J Biochem Mol Toxicol 2003; 17: 7-23.
130. Blum R, Gupta R, Burger PE, Ontiveros CS, Salm SN, Xiong X, Kamb A, Wesche H, Marshall L, Cutler G, et al. Molecular signatures of prostate stem cells reveal novel signaling pathways and provide insights into prostate cancer. PLoS One 2009; 4: e5722.
131. Chute JP, Muramoto GG, Whitesides J, Colvin M, Safi R, Chao NJ, McDonnell DP. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci USA 2006; 103: 11707-11712.
132. Patel M, Lu L, Zander DS, Sreerama L, Coco D, Moreb JS. ALDH1A1 and ALDH3A1 expression in lung cancers: Correlation with histologic type and potential precursors. Lung Cancer 2008; 59: 340-349.
133. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-567.
134. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009; 7: 330-338.
135. Visus C, Ito D, Amoscato A, Maciejewska-Franczak M, Abdelsalem A, Dhir R, Shin DM, Donnenberg VS, Whiteside TL, DeLeo AB. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res 2007; 67: 10538-10545.
136. Storms RW, Trujillo AP, Springer JB, Shah L, Colvin OM, Ludeman SM, Smith C. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci USA 1999; 96: 9118-9123.
137. Liu LL, Fu D, Ma Y, Shen XZ. The power and the promise of liver cancer stem cell markers. Stem Cells Dev 2011; 20: 2023-2030.
138. Broadley KW, Hunn MK, Farrand KJ, Price KM, Grasso C, Miller RJ, Hermans IF, McConnell MJ. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme. Stem Cells 2011; 29: 452-461.
139. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10: R25.
140. Pearce DJ, Bonnet D. The combined use of Hoechst efflux ability and aldehyde dehydrogenase activity to identify murine and human hematopoietic stem cells. Exp Hematol 2007; 35: 1437-1446.
141. Pierre-Louis O, Clay D, Brunet de la Grange P, Blazsek I, Desterke C, Guerton B, Blondeau C, Malfuson JV, Prat M, Bennaceur-Griscelli A, et al. Dual SP/ALDH functionalities refine the human hematopoietic Lin-CD34+CD38- stem/progenitor cell compartment. Stem Cells 2009; 27: 2552-2562.
142. Liang D, Shi Y. Aldehyde dehydrogenase-1 is a specific marker for stem cells in human lung adenocarcinoma. Med Oncol 2011; Epub ahead of print.
143. Su J, Xu XH, Huang Q, Lu MQ, Li DJ, Xue F, Yi F, Ren JH, Wu YP. Identification of cancer stem-like CD44+ cells in human nasopharyngeal carcinoma cell line. Arch Med Res 2011; 42: 15-21.
144. Wilkerson MJ. Principles of Flow Cytometry and Cell Sorting. 2004;
145. Gray DW, Gohde W, Carter N, Heiden T, Morris PJ. Separation of pancreatic islets by fluorescence-activated sorting. Diabetes 1989; 38 ( Suppl 1): 133-135.
146. Givan AL. Flow cytometry: An introduction. Methods Mol Biol 2011; 699: 1-29.
147. Herzenberg LA, Parks D, Sahaf B, Perez O, Roederer M. The history and future of the fluorescence activated cell sorter and flow cytometry: A view from Stanford. Clin Chem 2002; 48: 1819-1827.
148. Schmid I, Lambert C, Ambrozak D, Marti GE, Moss DM, Perfetto SP. International society for analytical cytology biosafety standard for sorting of unfixed cells. Cytometry A 2007; 71A: 414-437.
149. Basu S, Campbell HM, Dittel BN, Ray A. Purification of specific cell population by fluorescence activated cell sorting (FACS). J Vis Exp 2010;41:1546.
150. Seidl J, Knuechel R, Kunz-Schughart LA. Evaluation of membrane physiology following fluorescence activated or magnetic cell separation. Cytometry 1999; 36: 102-111.
151. Jochem FJ. Short-term physiologic effects of mechanical flow sorting and the Becton-Dickinson cell concentrator in cultures of the marine phytoflagellata Emiliania huxleyi and Micromonas pusilla. Cytometry A 2005; 65: 77-83.
152. Brando B, Gohde WJr, Scarpati B, D'Avanzo G. The vanishing counting bead phenomenon: Effect on absolute CD34+ cell counting in phosphate-buffered saline-diluted leukapheresis samples. Cytometry 2001; 43: 154-160.
153. Arnold LW, Lannigan J. Practical issues in high-speed cell sorting. Curr Protoc Cytom 2010; 24: 1-30.
154. Mathews LA, Crea F, Farrar WL. Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation 2009; 78: 1-17.
155. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, Pandiella A, Rezola R, Martin AG. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 2011; Epub ahead of print.
156. Liu CG, Lu Y, Wang BB, Zhang YJ, Zhang RS, Chen B, Xu H, Jin F, Lu P. Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg 2011; 253: 1165-1171.
157. Okano H, Imai T, Okabe M. Musashi: A translational regulator of cell fate. J Cell Sci 2002; 115: 1355-1359.
158. Bolos V, Blanco M, Medina V, Aparicio G, Diaz-Prado S, Grande E. Notch signalling in cancer stem cells. Clin Transl Oncol 2009; 11: 11-19.
159. Cattaneo E, McKay R. Proliferation and differentiation of neuronal stem cells regulated by nerve growth factor. Nature 1990; 347: 762-765.
160. Moon JH, Kwon S, Jun EK, Kim A, Whang KY, Kim H, Oh S, Yoon BS, You S. Nanog-induced dedifferentiation of p53-deficient mouse astrocytes into brain cancer stem-like cells. Biochem Biophys Res Commun 2011; 412: 175-181.
161. Rhee WJ, Bao G. Simultaneous detection of mRNA and protein stem cell markers in live cells. BMC Biotechnol 2009; 9: 30.
162. Nitin N, Santangelo PJ, Kim G, Nie S, Bao G. Peptide-linked molecular beacons for efficient delivery and rapid mRNA detection in living cells. Nucleic Acids Res 2004; 32: e58.
163. Santangelo PJ, Nix B, Tsourkas A, Bao G. Dual FRET molecular beacons for mRNA detection in living cells. Nucleic Acids Res 2004; 32: e57.